Stay updated on CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial
Sign up to get notified when there's something new on the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page.

Latest updates to the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page's revision label updated from v3.5.3 to v3.5.4, indicating a small maintenance update to the page. No study details or user-facing content were modified.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThese changes update the page’s revision history with new date stamps and a new revision tag (v3.5.3), and remove older revision dates. This indicates metadata versioning activity for the page rather than changes to the study content or outcomes.SummaryDifference0.3%

- Check41 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This is a minor site update with no changes to the study information.SummaryDifference0.0%

- Check49 days agoChange DetectedNo additions or deletions detected; the page content appears unchanged.SummaryDifference0.0%

- Check63 days agoChange DetectedThe inclusion criteria were expanded and clarified to define bone marrow and organ function thresholds, bleeding risk, and concomitant therapies (NSAIDs, antiplatelets, and anticoagulants), as well as requirements related to GI stents and endoscopic assessment. A previous blanket criterion of 'Normal bone marrow and organ function' was replaced with explicit definitions.SummaryDifference0.7%

- Check77 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page.